Abstract:Objective:To evaluate whether raloxifene can affect periodontitis-associated bone loss in osteoporotic rats. Methods:Thirty two three to four months old female SD rats were randomly divided into four groups as following: sham operated, ovariectomized(OVX), ovariectomized plus estrogen administration(EST) and ovariectomized plus raloxifene administration(RAL). After one week, steel-wire was placed around one of the lower first molar of all rats to induce periodontal diseases. Seven weeks later, rats were sacrificed and the specimens routinely processed. Body weight, bone mineral density(BMD), bone histomorphometry and serum biochemical indices were investigated. Results:The body weight of the OVX rats were significantly increased(P0.01). But BMD of total body, lumbar spine and femur in OVX rats were lower than those in the rats treated with raloxifene and estrogen. Compared with the OVX,the alkaline phosphatase and bone γ-carboxyglutamic acid protein in serum of RAL and EST were obviously decreased while the estradiol was increased(P0.05). Histomorphometry indicated the raloxifene and estrogen can prevented ovariectomized induced bone loss. Intergroup analysis revealed that an estrogen-deficient state significantly increased bone loss resulting from periodontitis and could be prevented by estrogen and raloxifene administration (0.33±0.02, 0.18±0.02, 0.19±0.02, 0.20±0.01 for OVX, RAL, EST and SHAM)(P0.01). Conclusion:Raloxifene administration can prevent bone loss to reduce osteoporosis in ovariectomized rats and prohibit periodontitis-associated alveolar bone resorption.

Effects of Raloxifene Administration on the Periodontitis-Associated Bone Loss in Osteoporotic Rats